Shandong Yingsheng Biotechnology

Shandong Yingsheng Biotechnology is a provider of in vitro diagnostic kits and clinical mass spectrometry solutions, operating a comprehensive product platform spanning analytical instruments, automated sample preparation systems, and diagnostic reagents. The company has developed a genetic testing platform and a mass spectrometry detection platform covering birth defect screening, disease prevention, and human health services. Its analytical instrument portfolio includes high-performance liquid chromatography tandem mass spectrometry systems (YS EXACT 9900MD, 9050MD, HyperQuant, SmartQuant), inductively coupled plasma mass spectrometry (YS EXT 8600MD), gas chromatography mass spectrometry (Animation-7080 GC/TQ), high-resolution Orbitrap mass spectrometry (YS HR 1080MD), and HPLC/UHPLC systems. Its automation platform includes the MSLET series automated liquid handling workstation, YS-600 multi-function sample preparation system, and YS EXT 7600MD fully automated fluorescence immunoassay analyzer. The company's IVD reagent offerings cover neonatal genetic metabolic disease screening, amino acid testing, vitamin detection, molecular diagnostics for hereditary deafness genes, and fluorescence immunoassay reagents. Yingsheng also provides clinical solutions for personalized medication, neonatal screening, mass spectrometry laboratory construction, and hereditary deafness gene detection. Founded in 2009 and headquartered in Jinan, China, the company has raised $14.5M in Series C funding from investors including C&D, Yuanbio Venture Capital, Sanze Venture Capital, CD Capital, CICC Capital, Far East Horizon, Huimei Capital, Hillhouse, and others.